Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has independently assessed the clinical benefits and effectiveness of Wegovy.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new licensed medicines represent a clinically and cost-effective use of resources.

Semaglutide (Wegovy) is recommended by NICE for both managing overweight and obesity and reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity.